NASDAQ:CALA - Calithera Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.39 +0.11 (+2.57 %) (As of 01/17/2019 08:00 AM ET)Previous Close$4.28Today's Range$4.23 - $4.4452-Week Range$3.55 - $9.35Volume217,400 shsAverage Volume230,210 shsMarket Capitalization$163.18 millionP/E RatioN/ADividend YieldN/ABeta2.3 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California. Receive CALA News and Ratings via Email Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALA Previous Symbol CUSIPN/A Webwww.calithera.com Phone650-870-1000Debt Debt-to-Equity RatioN/A Current Ratio13.66 Quick Ratio13.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25.95 million Price / Sales6.45 Cash FlowN/A Price / Cash FlowN/A Book Value$4.24 per share Price / Book1.04Profitability EPS (Most Recent Fiscal Year)($0.84) Net Income$-27,820,000.00 Net Margins-90.65% Return on Equity-31.73% Return on Assets-27.21%Miscellaneous Employees73 Outstanding Shares38,130,000Market Cap$163.18 million OptionableOptionable Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions What is Calithera Biosciences' stock symbol? Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA." How were Calithera Biosciences' earnings last quarter? Calithera Biosciences Inc (NASDAQ:CALA) released its quarterly earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.12. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 31.73%. View Calithera Biosciences' Earnings History. When is Calithera Biosciences' next earnings date? Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Calithera Biosciences. What price target have analysts set for CALA? 2 brokerages have issued 12-month price objectives for Calithera Biosciences' stock. Their predictions range from $14.00 to $14.00. On average, they expect Calithera Biosciences' share price to reach $14.00 in the next year. This suggests a possible upside of 218.9% from the stock's current price. View Analyst Price Targets for Calithera Biosciences. What is the consensus analysts' recommendation for Calithera Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences. Has Calithera Biosciences been receiving favorable news coverage? News coverage about CALA stock has been trending somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Calithera Biosciences earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the near term. Who are some of Calithera Biosciences' key competitors? Some companies that are related to Calithera Biosciences include Aurinia Pharmaceuticals (AUPH), Vectura Group (VEGPF), Kura Oncology (KURA), Ra Pharmaceuticals (RARX), CannTrust (CNTTF), ANI Pharmaceuticals (ANIP), Eagle Pharmaceuticals (EGRX), Basilea Pharmaceutica (BPMUF), ChemoCentryx (CCXI), Karyopharm Therapeutics (KPTI), Aptinyx (APTX), Cara Therapeutics (CARA), Viking Therapeutics (VKTX), ProQR Therapeutics (PRQR) and MacroGenics (MGNX). Who are Calithera Biosciences' key executives? Calithera Biosciences' management team includes the folowing people: Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 64)Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 44)Dr. Keith Orford, Sr. VP of Clinical Devel. (Age 46)Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 44)Ms. Jennifer McNealey, VP of Investor Relations & Strategy Who are Calithera Biosciences' major shareholders? Calithera Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.03%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences. Which major investors are buying Calithera Biosciences stock? CALA stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Calithera Biosciences. How do I buy shares of Calithera Biosciences? Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Calithera Biosciences' stock price today? One share of CALA stock can currently be purchased for approximately $4.39. How big of a company is Calithera Biosciences? Calithera Biosciences has a market capitalization of $163.18 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe. What is Calithera Biosciences' official website? The official website for Calithera Biosciences is http://www.calithera.com. How can I contact Calithera Biosciences? Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected] MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 231 (Vote Outperform)Underperform Votes: 173 (Vote Underperform)Total Votes: 404MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: What is intrinsic value?